LifeMD opened lower at $1.74, compared with its previous close of $1.78. In the last trading session, the stock traded between $1.63 and $1.79. It showed a downward intraday trend.
An investment of $100 made 2 years ago in LifeMD is now worth
$ 23.31
Resulting in a loss of
$ 76.69 (76.69%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.13 (-7.02%)
Day High
$1.79
Day Low
$1.63
Day Open
$1.74
Prev Close
$1.78
Volume
12,53,767
1W Return
-32.28%
1M Return
-35.48%
3M Return
-51.11%
6M Return
-62.30%
1Y Return
-67.29%
Market Cap ($ Mn)
80
PE Ratio
-
PB Ratio
18.88
PEG Ratio
-
ROE
-453.73%
ROCE
-63.40%
EPS (TTM)
$-0.16
1 Week
-32.28%
1 Month
-35.48%
3 Months
-51.11%
6 Months
-62.30%
9 Months
-43.13%
LifeMD reschedules Q3FY26 earnings release and conference call to Nov 12
LifeMD rescheduled its Q3FY26 earnings release to November 12, 2026. Press release expected at 4:05 pm ET, followed by call at 4:30 pm ET. Company provides virtual primary care and pharmacy services across 50 states.
6 days agoLifeMD signs deal to dispense Eli Lilly's self-pay GLP-1 medicines
LifeMD will directly dispense Eli Lilly's self-pay GLP-1 medicines. Program includes Zepbound and Foundayo for eligible US patients. Prescriptions fulfilled by LifeMD's licensed mail-order pharmacy. Patients purchase at Lilly's established self-pay price.
7 days agoLifeMD Q3FY26 Results: Earnings release set for November 9
LifeMD to report Q3FY26 results on November 9, 2026. Conference call scheduled for 8:30 am Eastern time. Results cover period ending September 30, 2026.
23 days agoLifeMD declares $0.55 dividend on Series A preferred stock
LifeMD declared a quarterly dividend of $0.5546875 per share on its Series A Preferred Stock. The dividend applies to the 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ: LFMDP). Payment is scheduled for October 15, 2026, with a record date of October 2, 2026. The Board of Directors authorized the cash distribution for preferred shareholders.
1mo agoBTIG maintains Buy on LifeMD, cuts price target to $9
BTIG analyst David Larsen keeps a Buy rating on LifeMD (NASDAQ: LFMD) but cuts the price target from $10 to $9. The move reflects a revised valuation outlook for the telehealth firm. Shareholders face reduced upside potential under the new target, though the investment recommendation remains positive.
3mo agoLifeMD Q2 Results: Revenue falls 3%, adjusted EBITDA loss widens
LifeMD reported Q2 2026 revenue of $47.3 million, down from $49.0 million year-over-year, as it transitions to branded GLP-1 therapies. Adjusted EBITDA swung to a loss of $3.5 million from a profit of $3.9 million, driven by higher acquisition costs. Gross margin expanded to ~89%, and active subscribers grew 20% to ~356,000. Full-year 2026 guidance was lowered to reflect launch costs for XYOSTED™ and a slower path to profitability, with management targeting positive adjusted EBITDA in H2 2026.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $506.04 | +0.32% | $1,05,708.21M | 14.01 | |
| $304.77 | -0.26% | $49,345.01M | 45.36 | |
| $292.97 | +0.93% | $23,316.90M | 10.31 | |
| $72.62 | +0.18% | $14,450.29M | 52.31 | |
| $79.43 | -1.38% | $14,087.55M | - | |
| $142.24 | -0.19% | $13,957.16M | 20.21 | |
| $22.22 | -2.29% | $11,935.03M | 11.93 | |
| $183.50 | +2.35% | $11,542.15M | 15.26 | |
| $186.19 | +0.59% | $10,862.51M | 27.11 | |
| $196.77 | +0.70% | $10,170.65M | 7.00 | |
| $103.03 | -0.49% | $8,522.13M | 34.79 | |
| $50.06 | +1.96% | $7,945.72M | 25.00 |
An investment of $100 made 2 years ago in LifeMD is now worth
$ 23.31
Resulting in a loss of
$ 76.69 (76.69%)
Note: Past profits do not guarantee future returns.
